NOV Mono expands operation in Germany
Pumps specialist aims to grow Mono Universal Parts across Europe
Svetla Laskova will be located in Berlin and Werner Potrafke will be working near Bochum. Both have language skills and sales and business development experience in the industrial and engineering sectors.
According to Martyn Turner, Universal Parts product manager at Mono, there is a significant market for progressing cavity (PC) pumps in Germany and until recently buyers have had to purchase replacement parts from the OEM.
‘Mono manufactures a range of Universal Parts designed for use in other branded PC pumps and these two new appointments will help us to promote the benefits of the brand and our PC pump technology to the waste water market in Germany,’ he said.
The full range of Mono Universal Parts includes rotors, stators, coupling rods, shafts, pins/bushes, seals and drive train assemblies for use in Seepex, Netzsch, PCM, Allweiler, Robbins & Myers, Bornemann and Orbit pumps.
Based in Manchester, UK, NOV Mono Group has more than 700 authorised distributors worldwide and employs around 750 people.
You may also like
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
![Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility]()
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
![Catalent launches ten-month gene-to-drug substance programme for complex biologics]()
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
![Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite]()
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale
Manufacturing
![Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month]()
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October